CVRX - NASDAQ
CVRx, Inc.
$5.39
-1.3%CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
At a Glance
Live SnapshotCVRx, Inc. Management Team
Mr. Jared Oasheim
Chief Financial Officer
Compensation
$517,269
Ms. Tonya A. Austin SPHR
Chief Human Resources Officer
Mr. Paul Verrastro
Chief Marketing & Strategy Officer
Compensation
$598,972
Dr. Philip B. Adamson M.D., M.Sc.
Chief Medical Officer
Mr. Robert Allen John
Chief Revenue Officer
Compensation
$535,875
Mr. Kevin Hykes
President, Chief Executive Officer & Director
Compensation
$940,130
Ms. Bonnie Handke M.B.A., R.N.
Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics
Ms. Jonelle R. Burnham
Vice President & General Counsel
Mr. Paul Pignato
Vice President of Research, Development and Operations
CVRx, Inc. Insider Positioning
During the last 12 months, insiders have purchased $300K and sold $988K worth of CVRX shares, resulting in $687K of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
47.4K
300.38K
16.0K
126.57K
+174K
+$174K
6-9 Months
0
0.00
84.9K
861.04K
-861K
-$861K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Jain Mudit K.
Director
$300K
Top Sellers
Johnson & Johnson
10 Percent Owner
$861K
Hykes Kevin
Director, Officer: Pres & Ceo
$61K
John Robert Allen
Officer: Chief Revenue Officer
$31K
Oasheim Jared
Officer: Chief Financial Officer
$14K
Verrastro Paul
Officer: Chief Mktg & Strat Officer
$10K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $687K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
CVRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 01, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 03, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 04, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 21, 2023 | June 05, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 25, 2022 | June 07, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.